1) Martin, M. Labormedizin in der Naturheilkunde. 3. Auflage, 2006.
2) Altun, A., Ugur-Altun, B. 2007. Melatonin: therapeutic and clinical utilization. Int J Clin Pract. 61(5):835-45.
3) Kunz, D. 2012. Melatonin taktet die innere Uhr neu. Neurologie & Psychiatrie. Vol. 14, Nr.1.
4) EFSA. 2011. Scientific opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13 (1) of Regulation (EC) No 1924/2006. EFSA Journal. 9
5) Salgado-Delgado, R. et al. 2011. Disruption of circadian rhythms: a crucial factor in the etiology of depression. Depress Res Treat. 2011:839743.
6) Reiter, R. J. et al. 1995. A review of the evidence supporting melatonin’s role as an antioxidant. Journal of Pineal Research. 18(1):1-11.
7) Flynn-Evans, E. E. et al. 2009. Total visual blindness is protective against breast cancer. Cancer Causes Control. 20(9):1753-6
8) Sánchez-Barceló, E. J. et al. 2003. Melatonin and mammary cancer: a short review. Endocr Relat Cancer. 10(2):153-9.
9) Verkasalo, P. K. et al. 1995. Inverse association between breast cancer incidence and degree of visual impairment in Finland. British Journal of Cancer. 80: 1459–1460.
10) Nooshinfar, E. et al. 2016. Melatonin promotes ATO-induced apoptosis in MCF-7 cells. Proposing novel therapeutic potential for breast cancer. Biomedicine & Pharmacotherapy. 83:456-465.
11) Mao, L. et al. 2016. Melatonin represses metastasis in Her2-postive human breast cancer cells by suppressing RSK2 expression. Molecular Cancer Research. 14(11):1159-1169.
Referenzen Interaktionen
Stargrove, M. B. et al. Herb, Nutrient and Drug Interactions: Clinical Implications and Therapeutic Strategies, 1. Auflage. St. Louis, Missouri: Elsevier Health Sciences, 2008.
Gröber, U. Mikronährstoffe: Metabolic Tuning –Prävention –Therapie, 3. Auflage. Stuttgart: WVG Wissenschaftliche Verlagsgesellschaft Stuttgart, 2011.
Gröber, U. Arzneimittel und Mikronährstoffe: Medikationsorientierte Supplementierung, 3. aktualisierte und erweiterte Auflage. Stuttgart: WVG Wissenschaftliche Verlagsgesellschaft Stuttgart, 2014.
Hilli, J. et al. 2008. The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism. J Clin Pharmacol. 48(8):986-94.
Reinberg, A.E. et al. 1996. Oral contraceptives alter circadian rhythm parameters of cortisol, melatonin, blood pressure, heart rate, skin blood flow, transepidermal water loss, and skin amino acids of healthy young women. Chronobiol Int. 13(3):199-211.
Wright, K.P. et al. 2000. Acute effects of bright light and caffeine on nighttime melatonin and temperature levels in women taking and not taking oral contraceptives. Brain Res. 873(2):310-7.
Circadin. 2 mg-Retardtabletten (Februar 2019). Gebrauchsinformation: Information für Patienten. Paris: RAD Neurim Pharmaceuticals EEC SARL.
|